and that targeting it — including through personalized approaches — may be a treatment pathway,” Heather Snyder, senior ...

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

AbbVie (ABBV) announced Monday that it is buying Aliada Therapeutics for $1.4 billion. The deal includes Aliada’s lead drug ...

The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...

A new therapy may delay Alzheimer's disease progression by years, according to a study by researchers at Texas A&M University ...

Research shows traditional herbs like jujube seeds may offer new pathways for dementia prevention and cognitive restoration.

The drug works by essentially forcing our cells to "spit out" dangerous protein clumps involved in Alzheimer's.

Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 ...

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after ...

Researchers have discovered that methazolamide, a glaucoma drug, can clear tau protein build-up in the brain, a key factor in dementias like Alzheimer's. This study, using zebrafish and mice models, s ...

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer’s diagnosis in ...

The news comes as the UK’s medicines regulator said Donanemab could be licensed for use in the UK. It is the second disease-modifying Alzheimer’s drug to be rejected by the National Institute ...